Neoadjuvant immunotherapy improves outcomes in high-risk melanoma patients.

Published Date: 02 Mar 2023

High-risk melanoma patients who received the drug pembrolizumab before or after surgery to remove the cancer had a higher risk of developing melanoma than those who did not have a similar condition that eliminated cancer cells.

Read Full News

Latest News


News All Time

Featured News
Featured Articles
Featured Events
Featured KOL Videos

1.

Scientists develop novel adjuvant delivery system to enhance cancer vaccine effectiveness

2.

The lack of psychiatrists may be addressed by community workers.

3.

Adaptive SABR-Used Hypofractionated Chemoradiation Showed Good Results in NSCLC.

4.

World's premier cancer institute faces crippling cuts and chaos

5.

Living in a more pedestrian-friendly area may reduce the risk of cancer and obesity-related diseases.


© Copyright 2026 Hidoc Dr. Inc.

Terms & Conditions - LLP | Inc. | Privacy Policy - LLP | Inc. | Account Deactivation
bot